PORTAGE BIOTECH INC (PRTG) Fundamental Analysis & Valuation
NASDAQ:PRTG • VGG7185A1369
Current stock price
6.81 USD
-0.15 (-2.16%)
At close:
7.4101 USD
+0.6 (+8.81%)
After Hours:
This PRTG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRTG Profitability Analysis
1.1 Basic Checks
- PRTG had negative earnings in the past year.
- PRTG had a negative operating cash flow in the past year.
- In the past 5 years PRTG always reported negative net income.
- PRTG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -304.13%, PRTG is not doing good in the industry: 93.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -304.13% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for PRTG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. PRTG Health Analysis
2.1 Basic Checks
- The number of shares outstanding for PRTG has been increased compared to 1 year ago.
- Compared to 5 years ago, PRTG has less shares outstanding
- PRTG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- PRTG has an Altman-Z score of -146.06. This is a bad value and indicates that PRTG is not financially healthy and even has some risk of bankruptcy.
- PRTG's Altman-Z score of -146.06 is on the low side compared to the rest of the industry. PRTG is outperformed by 97.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -146.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- PRTG has a Current Ratio of 2.02. This indicates that PRTG is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.02, PRTG is not doing good in the industry: 74.35% of the companies in the same industry are doing better.
- A Quick Ratio of 2.02 indicates that PRTG has no problem at all paying its short term obligations.
- The Quick ratio of PRTG (2.02) is worse than 73.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 2.02 |
3. PRTG Growth Analysis
3.1 Past
- PRTG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.66%, which is quite impressive.
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 62.98% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. PRTG Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRTG. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PRTG's earnings are expected to decrease with -27.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
5. PRTG Dividend Analysis
5.1 Amount
- No dividends for PRTG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRTG Fundamentals: All Metrics, Ratios and Statistics
6.81
-0.15 (-2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-25 2025-08-25
Earnings (Next)11-24 2025-11-24
Inst Owners2.21%
Inst Owner Change0%
Ins Owners35.54%
Ins Owner ChangeN/A
Market Cap15.53M
Revenue(TTM)N/A
Net Income(TTM)-6.77M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -304.13% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 2.02 | ||
| Altman-Z | -146.06 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.8%
OCF growth 3YN/A
OCF growth 5YN/A
PORTAGE BIOTECH INC / PRTG Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for PORTAGE BIOTECH INC?
ChartMill assigns a fundamental rating of 1 / 10 to PRTG.
What is the valuation status of PORTAGE BIOTECH INC (PRTG) stock?
ChartMill assigns a valuation rating of 0 / 10 to PORTAGE BIOTECH INC (PRTG). This can be considered as Overvalued.
Can you provide the profitability details for PORTAGE BIOTECH INC?
PORTAGE BIOTECH INC (PRTG) has a profitability rating of 0 / 10.
How financially healthy is PORTAGE BIOTECH INC?
The financial health rating of PORTAGE BIOTECH INC (PRTG) is 3 / 10.
Can you provide the expected EPS growth for PRTG stock?
The Earnings per Share (EPS) of PORTAGE BIOTECH INC (PRTG) is expected to decline by 0% in the next year.